Regenicin (Regenicin) Interest Expense : $-0.04 Mil (TTM As of Mar. 2023)

View and export this data going back to 2008. Start your Free Trial

What is Regenicin Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Regenicin's interest expense for the three months ended in Mar. 2023 was $ -0.01 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Regenicin's Operating Income for the three months ended in Mar. 2023 was $ -0.33 Mil. Regenicin's Interest Expense for the three months ended in Mar. 2023 was $ -0.01 Mil. Regenicin did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Regenicin Interest Expense Historical Data

The historical data trend for Regenicin's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Regenicin Interest Expense Chart

Regenicin Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Interest Expense

Get a 7-Day Free Trial

-0.02

-0.05

-0.04

Regenicin Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Interest Expense	Get a 7-Day Free Trial															-0.01	-0.01	-0.01	-0.01	-0.01

Regenicin Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04 Mil.

Regenicin (OTCPK:RGIN) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Regenicin's Interest Expense for the three months ended in Mar. 2023 was $-0.01 Mil. Its Operating Income for the three months ended in Mar. 2023 was $-0.33 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2023 was $0.00 Mil.

Regenicin's Interest Coverage for the quarter that ended in Mar. 2023 is calculated as

Regenicin did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Regenicin (Regenicin) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenicin Inc (OTCPK:RGIN) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10 High Court, Little Falls, NJ, USA, 07424

Website

https://www.regenicin.com

Regenicin Inc is a biotechnology company specializing in the development of regenerative cell therapies to restore the health of damaged tissues and organs. Its skin substitute product candidate comprises of NovaDerm. NovaDerm is a multi-layered tissue-engineered living skin prepared by utilizing autologous (patient's own) skin cells. It is a graftable cultured epithelium skin substitute containing both epidermal and dermal components with a collagen base. The technology has been clinically tested in Hundreds of pediatric, catastrophic burn patients.

Regenicin (Regenicin) Headlines

No Headlines